Search Results - "Gainor, J.F."

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer by Lin, J.J., Liu, S.V., McCoach, C.E., Zhu, V.W., Tan, A.C., Yoda, S., Peterson, J., Do, A., Prutisto-Chang, K., Dagogo-Jack, I., Sequist, L.V., Wirth, L.J., Lennerz, J.K., Hata, A.N., Mino-Kenudson, M., Nardi, V., Ou, S.-H.I., Tan, D.S.-W., Gainor, J.F.

“…Rearranged during transfection (RET) gene fusions are a validated target in non-small-cell lung cancer (NSCLC). RET-selective inhibitors selpercatinib…”
Get full text

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions by Piotrowska, Z., Costa, D.B., Oxnard, G.R., Huberman, M., Gainor, J.F., Lennes, I.T., Muzikansky, A., Shaw, A.T., Azzoli, C.G., Heist, R.S., Sequist, L.V.

“…There are currently no approved targeted therapies for non-small-cell lung cancer (NSCLC) patients with EGFR exon 20 insertions (ins20), a subgroup of EGFR…”
Get full text

Variation in Mechanisms of Acquired Resistance Among EGFR-Mutant NSCLC Patients With More Than 1 Postresistant Biopsy by Piotrowska, Z, Niederst, M.J, Mino-Kenudson, M, Morales-Oyarvide, V, Fulton, L, Lockerman, E, Howe, E, Gainor, J.F, Fidias, P, Heist, R.S, Shaw, A.T, Engelman, J.A, Sequist, L.V

Get full text

Acquired Resistance to Afatinib in EGFR-Mutant Lung Cancer by Sequist, L.V, Gerber, D.E, Fidias, P, Shaw, A.T, Temel, J.S, Heist, R.S, Gainor, J.F, Fulton, L, Kennedy, E.A, Muzikansky, A, Engelma, J.A

Get full text

Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer: Significance of Mutations in EGFR, ALK, or KRAS on Radiation Therapy Response and Survival by Mak, K.S, Gainor, J.F, Niemierko, A, Oh, K.S, Willers, H, Choi, N.C, Loeffler, J.S, Sequist, L.V, Shaw, A.T, Shih, H.A

Get full text

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression by Aguilar, E.J., Ricciuti, B., Gainor, J.F., Kehl, K.L., Kravets, S., Dahlberg, S., Nishino, M., Sholl, L.M., Adeni, A., Subegdjo, S., Khosrowjerdi, S., Peterson, R.M., Digumarthy, S., Liu, C., Sauter, J., Rizvi, H., Arbour, K.C., Carter, B.W., Heymach, J.V., Altan, M., Hellmann, M.D., Awad, M.M.

“…In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1) expression on ≥50% of tumor cells, first-line treatment with the PD-1 inhibitor…”
Get full text

ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research by Belli, C., Penault-Llorca, F., Ladanyi, M., Normanno, N., Scoazec, J.-Y., Lacroix, L., Reis-Filho, J.S., Subbiah, V., Gainor, J.F., Endris, V., Repetto, M., Drilon, A., Scarpa, A., André, F., Douillard, J.-Y., Curigliano, G.

“…Aberrant activation of RET is a critical driver of growth and proliferation in diverse solid tumours. Multikinase inhibitors (MKIs) showing anti-RET activities…”
Get full text

1388P Real-world prognostic value of RET fusions in advanced non-small cell lung cancer (aNSCLC) by Gadgeel, S.M., Zhang, Q., Lin, H., Fajardo, O., Trinh, H., Arndorfer, S., Kong, S., Rahman, A., Li, S., Archer, V.R., Gainor, J.F.

Get full text

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors by Hellmann, M.D., Kim, T.-W., Lee, C.B., Goh, B.-C., Miller, W.H., Oh, D.-Y., Jamal, R., Chee, C.-E., Chow, L.Q.M., Gainor, J.F., Desai, J., Solomon, B.J., Das Thakur, M., Pitcher, B., Foster, P., Hernandez, G., Wongchenko, M.J., Cha, E., Bang, Y.-J., Siu, L.L., Bendell, J.

“…Preclinical evidence suggests that MEK inhibition promotes accumulation and survival of intratumoral tumor-specific T cells and can synergize with immune…”
Get full text

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial by Griesinger, F., Curigliano, G., Thomas, M., Subbiah, V., Baik, C.S., Tan, D.S.W., Lee, D.H., Misch, D., Garralda, E., Kim, D.-W., van der Wekken, A.J., Gainor, J.F., Paz-Ares, L., Liu, S.V., Kalemkerian, G.P., Houvras, Y., Bowles, D.W., Mansfield, A.S., Lin, J.J., Smoljanovic, V., Rahman, A., Kong, S., Zalutskaya, A., Louie-Gao, M., Boral, A.L., Mazières, J.

“…RET fusions are present in 1%-2% of non-small-cell lung cancer (NSCLC). Pralsetinib, a highly potent, oral, central nervous system-penetrant, selective RET…”
Get full text

Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50 by Gainor, J.F., Rizvi, H., Jimenez Aguilar, E., Skoulidis, F., Yeap, B.Y., Naidoo, J., Khosrowjerdi, S., Mooradian, M., Lydon, C., Illei, P., Zhang, J., Peterson, R., Ricciuti, B., Nishino, M., Zhang, J., Roth, J.A., Grishman, J., Anderson, D., Little, B.P., Carter, B.W., Arbour, K., Sauter, J.L., Mino-Kenudson, M., Heymach, J.V., Digumarthy, S., Shaw, A.T., Awad, M.M., Hellmann, M.D.

“…Immune checkpoint inhibitors (ICIs) are standard therapies for patients with advanced non-small-cell lung cancer (NSCLC) and a programmed death-ligand 1…”
Get full text

28P Dose determination and pharmacokinetics (PK) of pralsetinib: Results from the phase I ARROW study by Gainor, J.F., Taylor, M., Ou, S-H.I., Garralda, E., Brose, M.S., Parepally, J., Zhang, H., Rahal, C., Zalutskaya, A., Subbiah, V.

Get full text

Chemotherapy and programmed cell death protein 1/programmed death-ligand 1 inhibitor combinations for tyrosine kinase inhibitor-resistant, epidermal growth factor receptor-mutated non-small-cell lung cancer: a meta-analysis by Piotrowska, Z., Yeap, B.Y., Gainor, J.F.

“…The role of adding immune checkpoint inhibitors to chemotherapy in tyrosine kinase inhibitor (TKI)-resistant, epidermal growth factor receptor (EGFR)-mutant…”
Get full text

1256TiP Phase III study of pembrolizumab (Pembro) with concurrent chemoradiation therapy (CCRT) followed by pembro with or without olaparib (Ola) vs CCRT followed by durvalumab (Durva) in unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC): KEYLYNK-012 by Jabbour, S., Cho, B.C., Bria, E., Kato, T., Bhosle, J., Gainor, J.F., Reguart, N., Wang, L., Morgensztern, D., Gurary, E.B., Ashraf, T.B., Lara-Guerra, H., Reck, M.

Get full text

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis by Borghaei, H., Ciuleanu, T.-E., Lee, J.-S., Pluzanski, A., Caro, R. Bernabe, Gutierrez, M., Ohe, Y., Nishio, M., Goldman, J., Ready, N., Spigel, D.R., Ramalingam, S.S., Paz-Ares, L.G., Gainor, J.F., Ahmed, S., Reck, M., Maio, M., O’Byrne, K.J., Memaj, A., Nathan, F., Tran, P., Hellmann, M.D., Brahmer, J.R.

“…First-line nivolumab plus ipilimumab prolongs survival versus chemotherapy in advanced non-small-cell lung cancer (NSCLC). We further characterized clinical…”
Get full text

KEYLYNK-012: A Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy (CCRT) Followed by Pembrolizumab With or Without Olaparib vs. CCRT Followed by Durvalumab in Unresectable, Locally Advanced, Stage III Non‒Small-Cell Lung Cancer by Jabbour, S.K., Cho, B.C., Bria, E., Kato, T., Bhosle, J., Gainor, J.F., Reguart, N., Wang, L., Morgensztern, D., Gurary, E.B., Ashraf, T.B., Lara-Guerra, H., Reck, M.

“…Pembrolizumab, an anti‒PD-1 antibody is standard of care therapy for metastatic non‒small-cell lung cancer (NSCLC) as monotherapy and in combination with…”
Get full text

Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC) by Lee, D.H., Subbiah, V., Gainor, J.F., Taylor, M.H., Zhu, V.W., Doebele, R.C., Lopes, G., Baik, C., Garralda, E., Gadgeel, S.M., Kim, D.-W., Turner, C.D., Palmer, M., Miller, S., Curigliano, G.

Get full text

1966P - Treatment with BLU-667, a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and thyroid cancer by Curigliano, G., Subbiah, V., Gainor, J.F., Lee, D.H., Taylor, M.H., Zhu, V., Doebele, R.C., Lopes, G., Baik, C., Garralda, E., Gadgeel, S.M., Kim, D.-W., Turner, C.D., Palmer, M., Miller, S.

“…BLU667, an investigational agent, is a potent and selective inhibitor of oncogenic rearranged during transfection (RET) alterations and predicted resistance…”
Get full text

Treatment with BLU-667, a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and thyroid cancer by Curigliano, G., Subbiah, V., Gainor, J.F., Lee, D.H., Taylor, M.H., Zhu, V., Doebele, R.C., Lopes, G., Baik, C., Garralda, E., Gadgeel, S.M., Kim, D.-W., Turner, C.D., Palmer, M., Miller, S.

Get full text

A systematic rapid autopsy program tracks temporal and spatial heterogeneity of human tumors and identifies mechanisms of resistance to targeted therapies by Walmsley, C.S., Juric, D., Bardia, A., Henderson, L., Gurski, J., Stone, J.R., Pinto, C., Isakoff, S.J., Fitzgerald, D.M., Gainor, J.F., Goyal, L., Broudo, M.

Get full text